NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Read More…
Industry, Sector and Symbol
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Phone239-768-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$276.74 million
Profitability
Miscellaneous
Employees1,500
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings results on Tuesday, July, 30th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.05 by $0.02. The medical research company earned $101.71 million during the quarter, compared to analyst estimates of $97.32 million. NeoGenomics had a return on equity of 4.97% and a net margin of 0.57%. The firm's quarterly revenue was up 50.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 EPS. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of $0.23-0.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $388-402 million, compared to the consensus revenue estimate of $393.32 million.
What price target have analysts set for NEO?
8 analysts have issued 12-month target prices for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' share price to reach $23.50 in the next year. This suggests that the stock has a possible downside of 7.9%. View Analyst Price Targets for NeoGenomics.
What is the consensus analysts' recommendation for NeoGenomics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.
Has NeoGenomics been receiving favorable news coverage?
Media headlines about NEO stock have been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NeoGenomics earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for NeoGenomics.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include Array Biopharma (ARRY), West Pharmaceutical Services (WST), Bausch Health Companies (BHC), Varian Medical Systems (VAR), Bio-Rad Laboratories (BIO), BioMerieux (BMXMF), Ionis Pharmaceuticals (IONS), Canopy Growth (CGC), Bio-Rad Laboratories (BIO.B), Novocure (NVCR), Ono Pharmaceutical (OPHLF), ProMetic Life Sciences (PLI), Davita (DVA), Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of NeoGenomics own?
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
- Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
- Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)
- Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.37%), Vanguard Group Inc. (7.87%), Janus Henderson Group PLC (4.18%), Janus Henderson Group PLC (4.18%), Eagle Asset Management Inc. (2.83%) and Brown Advisory Inc. (2.43%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.
Which major investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, Bank of New York Mellon Corp, First Light Asset Management LLC, Cowen Prime Services LLC, Jefferies Group LLC, Invesco Ltd. and 1492 Capital Management LLC. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.
Which major investors are buying NeoGenomics stock?
NEO stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Marshall Wace LLP, BlackRock Inc., Nuveen Asset Management LLC, Wells Fargo & Company MN, Point72 Asset Management L.P., Panagora Asset Management Inc. and Lisanti Capital Growth LLC. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $25.51.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $2.65 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.
What is NeoGenomics' official website?
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
